Company Description
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors.
In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis; and AG019, which is in Phase 1b/2a trial, to treat type 1 diabetes mellitus.
Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications.
The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020.
Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 143 |
| CEO | Helen Sabzevari |
Contact Details
Address: 20374 Seneca Meadows Parkway Germantown, Maryland 20876 United States | |
| Phone | 301 556 9900 |
| Website | precigen.com |
Stock Details
| Ticker Symbol | PGEN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001356090 |
| CUSIP Number | 74017N105 |
| ISIN Number | US74017N1054 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Helen Sabzevari MPH, Ph.D. | President, Chief Executive Officer and Director |
| Randal J. Kirk J.D. | Executive Chairman |
| Harry Thomasian Jr. | Chief Financial Officer |
| Rutul R. Shah | Chief Operating Officer |
| Donald P. Lehr J.D., Ph.D. | Chief Legal Officer and Corporate Secretary |
| Phil Tennant | Chief Commercial Officer |
| Steven M. Harasym | Vice President and Head of Investor Relations |
| Rob Russell | Vice President and Head of Human Resources |
| Dr. Douglas E. Brough Ph.D. | Senior Vice President and Head of Research |
| Dr. Bryan T. Butman Ph.D. | Senior Vice President and Head of CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 19, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 18, 2025 | 8-K | Current Report |
| Aug 18, 2025 | 8-K | Current Report |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Jun 30, 2025 | 8-K | Current Report |
| May 16, 2025 | ARS | Filing |
| May 16, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 16, 2025 | DEF 14A | Other definitive proxy statements |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |